Research programme: cochleate based therapeutics - Matinas Biopharma

Drug Profile

Research programme: cochleate based therapeutics - Matinas Biopharma

Alternative Names: Encochleated ibuprofen - Matinas BioPharma; Encochleated influenza vaccine - Matinas BioPharma; Encochleated siRNA; RNAi therapeutics

Latest Information Update: 02 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Aquarius Biotechnologies; Matinas BioPharma; Rutgers
  • Class Catechols; Nonsteroidal anti-inflammatories; Omega 3 fatty acids; Phenylpropionates; Small interfering RNA; Small molecules; Vaccines
  • Mechanism of Action Cyclooxygenase inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inflammation; Influenza virus infections; Unspecified; Viral infections

Most Recent Events

  • 24 Apr 2017 Preclinical trials in Viral infections in USA (PO, IM)
  • 26 Oct 2016 Pharmacodynamics data from preclinical studies in Influenza virus infections presented at IDweek 2016
  • 26 Oct 2016 Preclinical trials in Influenza virus infections in USA (PO, Intranasal) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top